Media Room
New Study: the PCA3 test could be useful to predict the outcome of an initial prostate biopsy
April 22, 2010
New studies show DiagnoCure’s PCA3 prostate cancer marker can help guide repeat prostate biopsy decisions and predict risk of aggressive cancer
March 8, 2010, 09:40
- Abstract 1
- Abstract 2
- Press release (PDF : 116.46 K)
Beginning of a U.S. clinical study intended to secure U.S. FDA regulatory approval of the PROGENSA PCA3 assay
August 27, 2009
Videos
Corporate Information
- Corporate Profile (PDF)
- Corporate Brochure (PDF)
- Pipeline
Logos
- DiagnoCure – Color (PNG)
- DiagnoCure – Black & White (PNG)
- DiagnoCure Oncology Laboratories – Color (PNG)
- DiagnoCure Oncology Laboratories – Black & White (PNG)
Contact
Paule De Blois, MBA
Senior Vice President, Operations
(418) 527-6100
communications@diagnocure.com